A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Grants and Contracts Details

StatusFinished
Effective start/end date3/14/191/29/21

Funding

  • Vertex Pharmaceuticals Inc: $48,574.00